It has been a rough few seasons for Novo Nordisk (NYSE:NVO) investors, as the company’s share price has tumbled some 60% over the past twelve

Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo Nordisk stock currently costs less than 14 times earnings.

Lilly’s weight-loss medications Mounjaro and Zepbound are gaining market share on Novo’s Wegovy and Ozempic, but investors remain unconvinced. It’s been a week of wins for Eli Lilly’s weight-loss drugs.